Literature DB >> 9180182

Immunodominant domains present on the Bordetella pertussis vaccine component filamentous hemagglutinin.

E Leininger1, S Bowen, G Renauld-Mongénie, J H Rouse, F D Menozzi, C Locht, I Heron, M J Brennan.   

Abstract

To identify immunologically important domains on filamentous hemagglutinin (FHA), a Bordetella pertussis protein included in new acellular pertussis vaccines (ACPVs), a series of monoclonal antibodies, sera from infants vaccinated with ACPVs or whole cell pertussis vaccine (WCPV), and sera from patients with pertussis were analyzed by immunoblots containing FHA fragments and recombinant FHA proteins. Immunodominant domains located at the COOH-terminus of FHA (type I domain) and near the NH2-terminus (type II domain) were defined by the reactivity with monoclonal antibodies. The sera from patients with pertussis and sera from infants vaccinated with WCPV or with 6 different investigational ACPVs specifically recognized well-defined regions within the type I and type II domains. Identification of these prominent immunologic epitopes on FHA should be useful for the construction of more well-defined pertussis vaccines and for the interpretation of human serologic responses, which may correlate with efficacy of pertussis vaccines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180182     DOI: 10.1086/516475

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Subtilisin-like autotransporter serves as maturation protease in a bacterial secretion pathway.

Authors:  L Coutte; R Antoine; H Drobecq; C Locht; F Jacob-Dubuisson
Journal:  EMBO J       Date:  2001-09-17       Impact factor: 11.598

2.  Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.

Authors:  Zhang Jinyong; Zhang Xiaoli; Zhang Weijun; Guo Ying; Guo Gang; Mao Xuhu; Zou Quanming
Journal:  Mol Biol Rep       Date:  2010-09-28       Impact factor: 2.316

3.  Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.

Authors:  J B Knight; Y Y Huang; S A Halperin; R Anderson; A Morris; A Macmillan; T Jones; D S Burt; G Van Nest; S F Lee
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

4.  Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii.

Authors:  Song F Lee; Scott A Halperin; Jennifer B Knight; Aaron Tait
Journal:  Appl Environ Microbiol       Date:  2002-09       Impact factor: 4.792

5.  Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin.

Authors:  Ahmad H Hussein; Elisabeth M Davis; Scott A Halperin; Song F Lee
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

6.  Natural-host animal models indicate functional interchangeability between the filamentous haemagglutinins of Bordetella pertussis and Bordetella bronchiseptica and reveal a role for the mature C-terminal domain, but not the RGD motif, during infection.

Authors:  Steven M Julio; Carol S Inatsuka; Joseph Mazar; Christine Dieterich; David A Relman; Peggy A Cotter
Journal:  Mol Microbiol       Date:  2009-02-10       Impact factor: 3.501

7.  Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role.

Authors:  Sylvie Alonso; Nathalie Reveneau; Kévin Pethe; Camille Locht
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

8.  Antigenic analysis of Bordetella pertussis filamentous hemagglutinin with phage display libraries and rabbit anti-filamentous hemagglutinin polyclonal antibodies.

Authors:  D R Wilson; A Siebers; B B Finlay
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

9.  Comparative efficacy of intranasal and injectable vaccines in stimulating Bordetella bronchiseptica-reactive anamnestic antibody responses in household dogs.

Authors:  John A Ellis; Sheryl P Gow; Lindsey B Lee; Stacey Lacoste; Eileen C Ball
Journal:  Can Vet J       Date:  2017-08       Impact factor: 1.008

10.  Subcutaneous vaccination with attenuated Salmonella enterica serovar Choleraesuis C500 expressing recombinant filamentous hemagglutinin and pertactin antigens protects mice against fatal infections with both S. enterica serovar Choleraesuis and Bordetella bronchiseptica.

Authors:  Zhanqin Zhao; Yun Xue; Bin Wu; Xibiao Tang; Ruiming Hu; Yindi Xu; Aizhen Guo; Huanchun Chen
Journal:  Infect Immun       Date:  2008-02-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.